Љ

Print

Molecular Phamacology

Update : 2017-05-18

Overview

Our mission is to contribute cancer chemotherapy by creating new molecular-targeted drugs. To this end, we promote the discovery and the development of novel molecular-targeted drugs. We established a panel of cancer cell lines (JFCR39) and an accompanied database, which stored information about drug sensitivities and biological pathways of JFCR39. This is a unique research platform, and designated "Cancer Cell Informatics". The Cancer Cell Informatics can strongly support the research concerning the molecular-targeted therapy from basic research to applied science. Particularly, it is useful in drug discovery and in identification of molecular targets of novel chemicals and in analysis of their molecular pharmacology. By using Cancer Cell Informatics, we indeed indentified a novel PI3 kinase inhibitor, and further pushed it toward the translational research. We welcome and promote the collaboration with academic researchers and pharmaceutical industries.

Projects

  1. Development of "Cancer Cell Informatics", an information-rich platform for the research of molecular-targeted therapy
  2. Discovery and development of novel molecular-targeted drugs
  3. Development of PI3 kinase-targeted drugs
  4. Molecular pharmacology of anticancer drugs based on chemical and genomic information

Publications

Publications

Ohashi Y, Okamura M, Hirosawa A, Tamaki N, Akatsuka A, Wu KM, Choi HW, Yoshimatsu K, Shiina I, Yamori T, Dan S.
M-COPA, a Golgi Disruptor, Inhibits Cell Surface Expression of MET Protein and Exhibits Antitumor Activity against MET-Addicted Gastric Cancers.
Cancer Res. 2016;76(13):3895-3903.
Akatsuka A, Kojima N, Okamura M, Dan S, Yamori T.
A novel thiophene-3-carboxamide analog of annonaceous acetogenin exhibits antitumor activity via inhibition of mitochondrial complex I.
Pharmacol Res Perspect. 2016;4(4):e00246.
Isoyama S, Kajiwara G, Tamaki N, Okamura M, Yoshimi H, Nakamura N, Kawamura K, Nishimura Y, Namatame N, Yamori T, Dan S.
Basal expression of insulin-like growth factor 1 receptor determines intrinsic resistance of cancer cells to a phosphatidylinositol 3-kinase inhibitor ZSTK474.
Cancer Sci. 2015;106(2):171-178.
Dan, S., Okamura, M., Mukai, Y., Yoshimi, H., Inoue, Y., Hanyu, A., Sakaue-Sawano, A., Imamura, T., Miyawaki, A., Yamori, T.
ZSTK474, a specific phosphatidylinositol 3-kinase inhibitor, induces G1 arrest of the cell cycle in vivo.
Eur J Cancer, 48, 936-943 (2012)
Ohashi, Y., Iijima, H., Yamaotsu, N., Yamazaki, K., Sato, S., Okamura, M., Sugimoto, K., Dan, S., Hirono, S., Yamori, T.
AMF-26: a novel inhibitor of the Golgi system, targeting Arf1, an ADP-ribosylation factor 1, with potential for cancer therapy.
J Biol Chem, 287, 3885-3897 (2012)
Dan S, Okamura M, Seki M, Yamazaki K, Sugita H, Okui M, Mukai Y, Nishimura H, Asaka R, Nomura K, Ishikawa Y, Yamori T.
Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations.
Cancer Res 2010;70(12):4982-4994.
Yaguchi S, Fukui Y, Koshimizu I, Yoshimi H, Matsuno T, Gouda H, Hirono S, Yamazaki K, Yamori T.
Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor.
J Natl Cancer Inst 2006;98(8):545-556.

Contact

3-8-31, Ariake, Koto-ku, Tokyo 135-8550
Tel: +81-3-3520-0111 (Ext. 5432)
Fax: +81-3-3570-0484
E-mail: molpharm@jfcr.or.jp

Return to Top of Page